NCT04591431 2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2 Unknown
Clinical Trials
6 trialsNCT02049047 2022-09-10
ONC-2010-001
Istituto Clinico Humanitas
Phase 2 Completed
NCT00770120 2020-03-06
S0722: Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
SWOG Cancer Research Network
Phase 2 Completed
NCT00374140 2017-10-19
Phase II Trial of RAD001 (Everolimus) in Previously Treated Small Cell Lung Cancer
University of Pittsburgh
Phase 2 Completed
NCT00124280 2016-11-18
Study Investigating the Effect of Everolimus Monotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
Novartis
Phase 2 Completed
NCT01024946 2015-05-12
Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity
Memorial Sloan Kettering Cancer Center
Phase 2 Completed